Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I,Jemal A .2020 .GLOBOCAN esti-. Global cancer statistics, : .
Speiser DE,Ho PC,Verdeil G .2016 .Regulatory circuits of T cell function in cancer. Nat Rev Immunol, 80(10) : 599-611.
Mittal D,Gubin MM,Schreiber RD,Smyth MJ RD .2014 .New insights into cancer immunoediting and its three component phases Elimination, equilibrium and escape. Curr Opin Immunol, 01 : 16-25.
Li F,Li C,Cai X,Xie Z,Zhou L,Cheng B .2021 .The association between CD8+ tumour-in ltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. EClinicalMedicine, 101134 : 101134.
Zheng QM,Li YY,Wang YP,Li GX,Zhao MM,Sun ZG .2023 .Association between CD8+ tumour-in ltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis. Expert Rev Anticancer Ther, 2208351(6) : 643-59.
Moher D,Shamseer L,Clarke M,Ghersi D,Liberati A,Petticrew M .2015 .Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev, 10(1) : 1-9.
Haddaway NR,Page MJ,Pritchard CC,McGuinness LA .2022 .PRISMA2020: An R package and shiny app for producing PRISMA 2020-compliant ow diagrams, with interactivity for optimised digital transparency. Campbell Syst Rev, 10(2) : 1230.
Wells G,Shea B,O'Connell D,Peterson J,Welch V,Losos M .2021 .Newcastle-ottawa quality assessment scale cohort studies. (accessed on 28 January, : .
Tierney JF,Stewart LA,Ghersi D,Burdett S,Sydes MR .2007 .Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 10 : 1745.
Du X,Wen S,Shi R,Xia J,Wang R,Zhang Y .2023 .Peripheral blood lymphocytes di erentiation patterns in responses / outcomes to immune checkpoint blockade therapies in nonsmall cell lung cancer: A retrospective study. BMC Cancer, 10(1) : 83.
Lieskovan SH,Lisberg A,Zaretsky JM,Grogan TR,Rizvi H,Wells DK .2019 .Tumour characteristics associated with bene t from pembrolizumab in advanced non-small cell lung cancer. Clin Cancer Res, 18(16) : 1078-0432.
Kaira K,Yamaguchi O,Kawasaki T,Hashimoto K,Miura Y,Shiono A .2023 .Prognostic signi cance of tumour in ltrating lymphocytes on rst-line pembrolizumab e cacy in advanced non-small cell lung cancer. Discov Oncol, 10(1) : .
Koh YW,Han JH,Haam S,Lee HW .2022 .Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumour-in ltrating immune cells in non-small cell carcinoma. Front Oncol, 996634 : 996634.
Li P,Qin P,Fu X,Zhang G,Yan X,Zhang M .2021 .Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor. Ann Palliat Med, 10(3) : 3039-49.
de Rodas ML,Nagineni V,Ravi A,Datar IJ,Kenudson MM,Corredor G .2022 .Role of tumour in ltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. J Immunother Cancer, 10(6) : .
Mazzaschi G,Minari R,Zecca A,Cavazzoni A,Ferri V,Mori C .2020 .Soluble PD-L1 and circulating CD8+PD-1+ and NK cells enclose a prognostic and predictive immune e ector score in immunotherapy treated NSCLC patients. Lung Cancer, 07 : 1-11.
Niemeijer AN,Sahba S,Smit EF,Witte BIL,de Langen AJ,Thunnissen E. .2020 .Association of tumour and stroma PD-1, PDL1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy. Br J Cancer, 10(3) : 392-402.
Ottonello S,Genova C,Cossu I,Fontana V,Rijavec E,Rossi G .2020 .Association between response to nivolumab treatment and peripheral blood lymphocyte subsets in patients with non-small cell lung cancer. Front Immunol, 00125 : 125.
Uryvaev A,Passhak M,Hershkovits D,Sabo E,Sela GB .2018 .The role of tumour-in ltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med Oncol, 10(3) : 25.
Wu K,Xia B,Zhang J,Li X,Yang S,Zhang M .2022 .Positive correlation of peripheral CD8+ T lymphocytes with immunerelated adverse events and combinational prognostic value in advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors. Cancers, 10(15) : 3568.
Yan Y,Wang X,Liu C,Jia J .2022 .Association of lymphocyte subsets with e cacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: A retrospective study. BMC Pulm Med, 10(1) : 166.
Zugazagoitia J,Gupta S,Liu Y,Fuhrman K,Gettinger S,Herbst RS .2020 .Biomarkers associated with bene cial PD-1 checkpoint blockade in non-small cell lung cancer (NSCLC) identi ed using high-plex digital spatial pro lCinlign. Cancer Res, 20(16) : 1078-0432.
Liu B,Song Y,Liu D. .2017 .Recent development in clinical applicat i o n s o f P D - 1 a n d P D - L 1 a n t i b o d i e s f o r c a n c e r immunotherapy. J Hematol Oncol, 10(1) : 174.
Spranger S,Spaapen RM,Zha Y,Williams J,Meng Y,Ha TT .2013 .Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumour microenvironment is driven by CD8(+) T cells. Sci Transl Med, 10(200) : .
Pardoll DM .2012 .The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 10(4) : 252-64.
Alspach E,Lussier DM,Miceli AP,Kizhvatov I,DuPage M,Luoma AM .2019 .MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature, 10(7780) : 696-701.
Pyke RM,Thompson WK,Salem RM,Burgada JF,Zanetti M,Carter H M .2018 .Evolutionary pressure against MHC class II binding cancer mutations. Cell, 08(2) : 416-28.
Ahrends T,Spanjaard A,Pilzecker B,Babala N,Bovens A,Xiao Y .2017 .CD4+ T cell help confers a cytotoxic t cell e ector program including coinhibitory receptor downregulation and Increased tissue invasiveness. Immunity, 10(5) : 848-61.
Zander R,Schauder D,Xin G,Nguyen C,Wu X,Zajac A .2019 .CD4+ T cell help is required for the formation of a cytolytic CD8+ T cell subset that protects against chronic infection and cancer. Immunity, 10(6) : 1028-42.
Togashi Y,Shitara K,Nishikawa H K .2019 .Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol, 10(6) : 356-71.
Borst J,Ahrends T,Babala N,Melief CJM,Kastenmuller W. .2018 .CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol, 10(10) : 635-47.
Balanca CC,Salvioni A,Scarlata CM,Michelas M,Gomez CM,Roca CG .2021 .PD-1 blockade restores helper activity of tumour-in ltrating, exhausted PD-1hiCD39+ CD4 T cells. JCI Insight, 142513(2) : .
Bassez A,Vos H,Van Dyck L,Floris G,Arijs I,Desmedt C .2021 .A single-cell map of intratumoural changes during antiPD1 treatment of patients with breast cancer. Nat Med, 10(5) : 820-32.
Li K,Tandurella JA,Gai J,Zhu Q,Lim SJ,Thomas DL .2022 .Multi-omic analyses of changes in the tumour microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell, 10(11) : 1374-91.
An HJ,Chon HJ,Kim C .2021 .Peripheral blood-based biomarkers for immune checkpoint inhibitors. Int J Mol Sci, 10(17) : 9414.
Zhang F,Bai H,Gao R,Fei K,Duan J .2020 .Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer. Cancer Immunol Immunother, 10(12) : 2599-611.
Arasanz H,Zuazo M,Bocanegra A,Gato M,Aguillo MM,Morilla I .2020 .Early detection of hyperprogressive disease in non-small cell lung cancer by monitoring of systemic T cell dynamics. Cancers, 10(2) : 344.
Xia L,Wang H,Sun M,Yang Y,Yao C,He S .2021 .Peripheral CD4+ T cell signatures in predicting the responses to antiPD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer. Sci China Life Sci, 10(10) : 1590-601.
Fundytus A,Booth CM,Tannock IF .2021 .How low can you go? PDL1 expression as a biomarker in trials of cancer immunotherapy. Ann Oncol, 03(7) : 833-6.